Plant-Based Vaccines Market Revenue Opportunities By Key Players Operating Globally: Medicago Inc., Mitsubishi Tanabe Pharma Corporation, and Fraunhofer Center for Molecular Biotechnology (CMB)

Plant-based vaccines are derived from antigens produced in genetically modified plants that can be extracted and purified by conventional methods. These vaccines can either be consumed or applied to mucosal surfaces. Plants that are commonly used in production of vaccines are tobacco, potato, tomato, corn, and rice. Currently, there are several transgenic plants used in development of four different types of vaccines namely: viral vaccines, parasite vaccines, and bacterial vaccines.

Download PDF Brochure of Research Report:
https://www.coherentmarketinsights.com/insight/request-pdf/2004

Plant-based vaccines can be extensively manufactured at a very cheap cost. Currently, no plant-based vaccine has received approval from the US Food and Drug Administration (FDA), as these vaccines are classified under the genetically modified crop category. However, there are several plant-based vaccines in clinical trials, which are expected to receive approval from FDA during the forecast period.

Plant-Based Vaccines Market Drivers:
Increasing number of research and development activities by key players in the market and robust pipeline of plant-based vaccines is expected to be a major factor driving the global plant-based vaccines market growth during the forecast period. For instance, in 2017, Medicago Inc.—a Canada-based biopharmaceutical company that focuses on development of plant-based vaccines—initiated phase 3 clinical trial to evaluate efficacy of its seasonal quadrivalent influenza vaccine (QIV) candidate. The trial comprises around 10,000 subjects in the following countries: the U.S., Canada, Germany, the U.K., the Philippines, Finland, and Thailand. QIV was developed using a new virus-like particle (VLP) technology, which is an alternative to egg-based and cell-based production systems.

Furthermore, in 2017, researchers from the Arizona State University (ASU), in the U.S., developed the first plant-based Zika vaccine. According to the university, the newly developed plant-based Zika vaccine is safer, potent, and its production cost is much cheaper. Such robust pipeline of plant-based vaccines is expected to be a major factor in growth of the global plant-based vaccines market during the forecast period.

Plant-Based Vaccines Market Key Players

Key players operating in the global plant-based vaccines market include Medicago Inc., Mitsubishi Tanabe Pharma Corporation, iBio, Inc., Fraunhofer Center for Molecular Biotechnology (CMB), Protalix BioTherapeutics, and others.

Request For Customization of Research Report: https://www.coherentmarketinsights.com/insight/request-customization/2004

Plant-Based Vaccines Market Taxonomy:

The global plant based vaccines market is segmented on the basis of vaccine type, application, and region

By Vaccine Type-
• Bacterial Vaccines
• Viral Vaccines
• Parasite Vaccines
• Others

By Application-
• Influenza
• Zika Virus
• Ebola Virus
• Others

By Geography-
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.